A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
NCT01672450
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
Intratumoral Ipilimumab and Interleukin-2
Sponsor
University of Utah